TECX
Tectonic Therapeutic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.00
−0.77%Jun 10, 2026, 20:01 UTC
Tectonic Therapeutic completed enrollment in the TX45 APEX Phase 2 clinical trial for PH-HFpEF patients.
Source:
NASDAQ · Healthcare · Biotechnology · US
Jun 10, 2026, 20:01 UTC